

High Expression of PIGC Predicts Unfavorable Survival in Hepatocellular Carcinoma

This article was published in the following Dove Press journal:
Journal of Hepatocellular Carcinoma

Xufeng Guo¹
Shan Tian²
Pan Cao³
Yishan Xie¹
Weiguo Dong²

¹Department of Oncology, Renmin Hospital of Wuhan University, Wuhan, People's Republic of China; ²Department of Gastroenterology, Renmin Hospital of Wuhan University, Wuhan, People's Republic of China; ³Department of Infectious Disease, Renmin Hospital of Wuhan University, Wuhan, People's Republic of China

Purpose: The effects of phosphatidylinositol glycan anchor biosynthesis, class C (PIGC), in the progression of liver cancer are unknown. In this study, we attempted to clarify the clinical significance and mechanism of PIGC in hepatocellular carcinoma (HCC).

Patients and Methods: To explore the expression profiles, DNA methylation, mutation status, clinical relevance, and prognostic value of PIGC in patients with HCC, a series of bioinformatic databases and websites were searched. Moreover, numerous vitro experiments were performed to investigate the mechanism of PIGC in the regulation of cancerous liver cells.

Results: Expression of PIGC mRNA and protein was upregulated in cancerous liver specimens compared with normal liver tissues. High expression of PIGC mRNA was related to higher tumor grade, lymphatic metastasis, advanced TNM stage, and TP53 mutation. High expression of PIGC mRNA predicted more unfavorable overall survival (OS) (HR=1.7, P=0.0028) and disease-free survival (DFS) (HR=1.5, P=0.0067) in patients with liver cancer. The mutation rate of PIGC was 10%, and amplification was the most common mutant type. Expression of *PIGC* mRNA was negatively regulated by its DNA methylation ($r=-0.398$, $P<0.0001$). Moreover, silencing of *PIGC* in HepG2 cell line inhibited the proliferation and migration and led to cell cycle arrest at G0/G1 stage by reducing cyclinD1, CDK2, CDK4, and CDK6 expression, while overexpression of PIGC in Hcclm3 cell line revealed the opposite effect.

Conclusion: *PIGC* is related to aggressive clinical features, and overexpression of *PIGC* signifies worse survival in patients with HCC. *PIGC* promotes proliferation and migration of cancerous liver cells through the regulation of the cell cycle.

Keywords: hepatocellular carcinoma, PIGC, gene mutation, survival, cell cycle

Introduction

Liver cancer is one of the most common malignancies of the digestive system, with an increasing incidence rate over the past few years.¹ Liver cancer ranks fourth in terms of cancer-related deaths among all malignant tumors and only second to pancreatic cancer in gastrointestinal cancers.^{2,3} The mortality of liver cancer in the United States increased from 7.2 deaths per 100,000 to 10.3 deaths per 100,000 during 2000 and 2016.⁴ Liver cancer poses a considerable health burden around the world, and China accounts for half of the mortality each year.⁵ The overall prognosis of patients with liver cancer is generally poor, with a 5-year survival rate of 18%.² Although liver resection is effective, only 5–15% of early-stage liver cancer patients are eligible for surgical treatment.⁶ Sorafenib, a kinase inhibitor, seems to be promising in treating liver cancer patients in the advanced stage. However, drug resistance of sorafenib is obvious within half a year of initiating the regimen.⁷ Hepatocellular carcinoma (HCC) is a major type of liver cancer, and elucidating the

Correspondence: Weiguo Dong
Department of Gastroenterology, Renmin Hospital of Wuhan University, No. 99 Zhang Zhi-dong Road, Wuhan, 430060, People's Republic of China
Tel +86-027-88041911
Email Ddongweiguo@163.com

Correspondence: Yishan Xie
Department of Oncology, Renmin Hospital of Wuhan University, No. 99 Zhang Zhi-dong Road, Wuhan, 430060, People's Republic of China
Tel +86-027-88041911
Email I8502753963@163.com

exact molecular mechanism of HCC might be of substantial significance in the identification of novel therapeutical targets.

Phosphatidylinositol glycan anchor biosynthesis, class C (*PIGC*), a subunit of glycosylphosphatidylinositol (GPI)-GlcNAc transferase enzyme, is responsible for encoding endoplasmic reticulum related protein that is essential for the biosynthesis of GPI-anchor protein (GPI-AP).⁷ GPI-AP is reported to be involved in the regulation of immune signals and the activation of tyrosine kinase signaling pathways.^{9,10} Knocking out of the *PIGC* gene will lead to the absence of GPI-AP in cells.¹¹ In a recent study, it was revealed that mutations in the *PIGC* gene resulted in defective biosynthesis of GPI-APs, manifested by mental retardation and seizure disorders.¹² Moreover, *PIGC* single nucleotide polymorphism is associated with a high risk for obesity.¹³ A recent report demonstrated that the expression of *PIGC* is upregulated in triple-negative breast cancer, and this gene is regulated by miR-182.⁸ However, the role of *PIGC* in HCC is still unknown.

In our study, we investigated the gene expression, DNA methylation, and mutation of *PIGC* in HCC based on the TCGA-LIHC dataset. Thereafter, we performed the gene enrichment analysis of *PIGC*-correlated genes to determine the potential pathways of *PIGC* in HCC. Furthermore, we overexpressed and silenced the *PIGC* gene in cancerous liver cell lines and investigated the biological functions of *PIGC* in cancerous liver cell in vitro assays, for the first time.

Patients and Methods

Bioinformatics Analysis

Oncomine database¹⁴ (<https://www.oncomine.org>) was mined to determine the expression profiles of *PIGC* mRNA in human malignant tumors. Gene Expression Profiling Interactive Analysis¹⁵ (GEPIA) webpage (<http://gepia.cancer-pku.cn/>) was browsed to validate the expression profiles of *PIGC* mRNA based on the TCGA-LIHC dataset. The UALCAN website¹⁶ (<http://ualcan.path.uab.edu/index.html>) was searched to investigate the relationship between the *PIGC* mRNA level and common characteristics in HCC. cBioPortal database was logged in to explore the mutation of *PIGC* in HCC, and the co-expressed genes with significant correlation was identified. UCSC Xena¹⁷ (<https://xenabrowser.net/>) was utilized to study the potential correlation between the *PIGC* expression and DNA methylation. Kaplan–Meier plotter¹⁸

(<https://kmplot.com/analysis>) was adopted to determine whether *PIGC* expression was a biomarker for survival in patients with HCC. The ClueGO section in the Cytoscape software¹⁹ was used to analyze the biological pathways of *PIGC* co-expressed genes in HCC.

Collection of Cancerous Liver Tissues

We collected four pairs of cancerous liver specimens and adjacent normal tissues from the Department of Hepatobiliary Surgery, Renmin Hospital of Wuhan University between January 2021 and February 2021. All the fresh liver tissues were stored at -80°C for the Western blot analysis. This study was implemented under the Declaration of Helsinki. The Institutional Review Board of Renmin Hospital of Wuhan University reviewed and approved our study. All patients involved in this study provided the written informed consent.

Cell Culture and Transfection

Cancerous human liver cell lines (HepG2, Huh7, Hcclm3, and Hep3B) and a normal hepatocyte cell line (LO2) were obtained from China Center for Type Culture Collection (Wuhan, China). The above cell lines were cultured in Dulbecco's modified Eagle's medium (DMEM, HyClone, Logan, USA) mixed with 10% fetal bovine serum (FBS, Gibco, USA). The above cell lines were cultured in a humidified incubator filled with 95% air and 5% CO₂ at 37 °C. Cell transfection was performed using vectors used in the cell transfection and was provided by the RiboBio company (Guangzhou, China), including overexpression of *PIGC*, negative control, siRNA of *PIGC* (Si-*PIGC*-1:GCCCTAGTCTTCATTACTT; Si-*PIGC*-2:CCCTGCATGCCCTTCATCAT; Si-*PIGC*-3:GCCCTTCTGCTGATGTCTA) and siRNA negative control (Si-NC: GCCTCTTCGTATGCTA). Mock group was defined as cells transfected with only the transfection reagent.

Western Blot

The total protein of transfected cancerous liver cells was extracted through the extraction buffer for the total protein. After the protein (40 ug per hole) was separated by electrophoresis with 10% SDS-PAGE gel, the gels were then transferred to the PVDF membranes. The membranes were initially blocked with 5% nonfat milk and then incubated with the primary antibodies, including *PIGC* (novopro, 135229, dilution:1:1000), *Cyclin D1* (CST, #55506, dilution:1:1000), *CDK2* (CST, #18048, dilution:1:1000), *CDK4* (Sanying, Wuhan, 11026-1-AP, dilution:1:1000),

and *CDK6* (Abcam, ab241554, dilution:1:1000) and finally incubated with specific secondary antibody (HRP-Goat anti Rabbit, ASPEN, AS1107, dilution:1:10000).

CCK-8 Assay

Transfected cancerous liver cells were seeded into 96-well plates at a density of 1×10^4 cells per well. Cell Counting Kit-8 (Biyuntian biotechnology) reagent of 10 μ L was added to each well after 0 and 2 h. Cell viability of the intervened cells was detected using a microplate reader (DiaTek) at 450 nm absorbance.

Transwell Migration Assay

In the upper layer of the transwell plates, 10^5 cells were seeded, whereas the below chambers contained 600 μ L DMEM supplemented with 20% FBS. Cells that migrated to the bottom chambers were fixed with 70% ethanol for 20 min and then stained with crystal violet solution (AS1086, Aspen, Wuhan) for 10 min.

Flow Cytometric Assay

Transfected cells were collected and fixed in 70% ethanol for 30 min. Then, the fixed cells were stained with 50 μ g/ μ L propidium iodide solution for 30 min. Finally, the stained cells were analyzed with the flow cytometry (BD Biosciences).

Statistical Analysis

All statistical analyses were conducted via SPSS23.0 software and GraphPad Prism 7. Categorical and continuous parameters were presented as numbers with percentages and means with standard deviations, respectively. Differences of categorical parameters were checked with the chi-square or Fisher's exact test. Differences in the continuous parameters between the two groups were tested by student t or nonparametric method. Survival analyses were utilized to reveal the prognostic values of *PIGC* mRNA and methylation in HCC patients, and log rank test was applied to evaluate the survival difference. The correlation between *PIGC* mRNA expression and DNA methylation was evaluated by the Pearson correlation test. P value <0.05 was significant in all the statistical analyses.

Results

Expression and Clinical Relevance of *PIGC* mRNA in HCC

We extracted the Oncomine database to explore the expression profile of *PIGC* in human malignant cancers. As presented in [Figure 1A](#), *PIGC* was highly expressed in the liver, brain and CNS cancers, myeloma, esophageal cancer, and cervical cancer, while lowly expressed in leukemia and kidney cancer. We also searched the GEPIA website which was based on the TCGA database to validate the results from the Oncomine database. As shown in [Figure 1B](#), expression of *PIGC* mRNA was upregulated in HCC, glioblastoma multiforme, lymphoid neoplasm diffuse large b-cell lymphoma, pancreatic adenocarcinoma, and thymoma. Collectively, *PIGC* mRNA was upregulated in cancerous liver tissues than the correspondingly normal tissues. As presented in [Figure 2A and B](#), data from TCGA-LIHC showed that *PIGC* mRNA expression is much higher in cancerous liver specimens than that in normal liver tissues ($P < 0.0001$). To verify the different expressions of *PIGC* in HCC specimens and normal liver tissues, we collected four pairs of HCC specimens and precancerous lesions. As exhibited in [Figure S1](#), levels of *PIGC* protein in HCC specimens were remarkably higher than its precancerous lesions.

We utilized the UALCAN website to investigate the relationship between *PIGC* mRNA expression and clinical variables in HCC. As presented in [Figure 3](#), high levels of *PIGC* mRNA were associated with female patients ([Figure 3A](#)), young age ([Figure 3B](#)), high tumor grade ([Figure 3C](#)), lymph node metastasis ([Figure 3D](#)), advanced TNM stage ([Figure 3E](#)), and TP53 mutation ([Figure 3F](#)). We browsed the Kaplan–Meier plotter website to determine whether *PIGC* was a prognostic biomarker for patients with HCC. We selected the mean value of *PIGC* mRNA to divide HCC patients into the high *PIGC* group and low *PIGC* group. As exhibited in [Figure 4](#), HCC patients in high *PIGC* group experienced more discouraging overall survival (OS) time than patients in the low *PIGC* group (37.8 vs 71.0 months, [Figure 4A](#)). HCC patients with high expression of *PIGC* possessed worse disease-free survival (DFS) compared to those with low *PIGC* expression (48.43 vs 68.57 months, [Figure 4B](#)).

A

Analysis Type by Cancer	Cancer vs. Normal	Cancer vs. Cancer		Cancer Subtype Analysis						
		Cancer Histology	Multi-cancer	Clinical Outcome	Metastasis vs. Primary	Molecular Subtype: Biomarker	Molecular Subtype: Mutation	Pathology Subtype: Grade	Pathology Subtype: Stage	Patient Treatment Response
Bladder Cancer										
Brain and CNS Cancer	2	1	1	2						
Breast Cancer										
Cervical Cancer	1									
Colorectal Cancer										
Esophageal Cancer	1									
Gastric Cancer										
Head and Neck Cancer	1									
Kidney Cancer		2	1	1						
Leukemia		1								
Liver Cancer	3			1						
Lung Cancer										
Lymphoma										
Melanoma										
Myeloma	1									
Other Cancer										
Ovarian Cancer										
Pancreatic Cancer										
Prostate Cancer										
Sarcoma	1	1								
Significant Unique Analyses	10	3	3	2	3					
Total Unique Analyses	445	737	268							

B




Figure 1 Expression profiles of *PIGC* mRNA in human malignant tumors. (A) Oncomine database, (B) GEPIA website.




Figure 2 Correlation between *PIGC* mRNA expression and *PIGC* DNA methylation. **(A)** Heat map of *PIGC* expression and its DNA methylation in cancerous liver specimens and normal liver tissues. **(B)** *PIGC* mRNA expression is higher in cancerous liver tissues (N=372) than that in normal liver tissues (N=49).




Figure 3 Association between expression of *PIGC* mRNA and clinical characteristics in liver cancer from the UALCAN database. **(A)** Gender, **(B)** age, **(C)** tumor grade, **(D)** N stage, **(E)** TNM stage, **(F)** TP53 mutation.

Significance of *PIGC* DNA Methylation in HCC

DNA methylation acts as the main epigenetic modification that is implicated in the transcriptional regulation of most genes, and abnormal DNA methylation is reported to be involved in the occurrence and progression of HCC.^{20,21} This study attempted to identify the association between *PIGC* mRNA expression and DNA methylation in HCC. The methylation levels of *PIGC* DNA in normal liver tissues

were significantly higher than that in cancerous liver tissues (Figure 5A). We found a negative association between *PIGC* mRNA expression and *PIGC* DNA methylation ($r=-0.398$, $P<0.0001$, Figure 5B), and this negative association could well explain the differential expressions of *PIGC* mRNA in cancerous liver specimens and normal tissues. Additionally, the methylation levels of 14 *PIGC* DNA CpG sites are listed in Figure 5C. Pearson correlation analysis was utilized to assess the relationship between *PIGC* mRNA expression and




Figure 4 Association between *PIGC* expression and survival in patients with liver cancer. Overexpression of *PIGC* correlates with worse overall survival (A) and disease-free survival (B) in patients with liver cancer. *PIGC* overexpression is correlated with worse overall survival in patients without viral hepatitis (C), but not in patients with viral hepatitis (D). Overexpression of *PIGC* is correlated with worse disease-free survival in patients without viral hepatitis (E), but not in patients with viral hepatitis (F).

methylation levels of 14 *PIGC* DNA CpG sites (Table S1), and we found that a moderate correlation existed in cg03748243 ($r=-0.479$, $P<0.0001$, Figure S2A) and weak correlations in cg02288969 ($r=-0.353$, $P<0.0001$, Figure S2B), cg16177739 ($r=-0.276$, $P<0.0001$, Figure S2C), and cg11841239 ($r=-0.278$, $P<0.0001$, Figure S2D). However, the survival analysis did not find any association between *PIGC* hypermethylation and OS (HR=1.151, $P=0.42$, Figure S3A) or DFS (HR=1.235, $P=0.281$, Figure S3B) in patients with HCC.

Correlation Between *PIGC* and Viral Hepatitis

Since most HCC in patients is attributed to viral hepatitis,^{22,23} so we specifically investigated the relationship between *PIGC* and viral hepatitis based on the TCGA-LIHC dataset. As clearly shown in Figure S4A, HCC patients with viral hepatitis (N=157) possessed much lower levels of *PIGC* mRNA (9.592 ± 0.169 vs 9.841 ± 0.054 log₂ (norm_count+1), $P<0.0001$) than those

without viral hepatitis (N=196). Then, we also checked the difference of *PIGC* DNA methylation between HCC patients with viral hepatitis and patients without viral hepatitis. However, no statistical difference was noticed between the two groups (0.403 ± 0.003 vs 0.405 ± 0.003 beta value, $P=0.499$, Figure S4B). Moreover, we mined the Kaplan-Meier plotter website to investigate the prognostic value of *PIGC* both in patients with viral hepatitis and individuals without viral hepatitis. The association between the overexpression of *PIGC* and poor OS or DFS only existed in HCC patients without viral hepatitis (Figure 4C and E), while it was absent in patients with viral hepatitis (Figure 4D and F).

PIGC Mutation in HCC

We logged on to the cBioPortal website to explore the mutation rate of *PIGC*. As shown in Figure 6A, the mutation rate of *PIGC* is 10% in patients with HCC based on the data from TCGA-LIHC. Moreover, statistical analysis was adopted to determine the possible association between




Figure 5 Relationship between *PIGC* methylation and *PIGC* mRNA expression in liver cancer. **(A)** Levels of *PIGC* DNA methylation are lower in cancerous liver tissues (N=379) compared with that in normal liver tissues (N=50). **(B)** A negative correlation ($r=-0.398$, $P<0.0001$) is observed between *PIGC* DNA methylation and *PIGC* mRNA expression. **(C)** Distribution of 14 *PIGC* DNA CpG sites in liver cancer and normal tissues.




Figure 6 *PIGC* gene mutation rate and its clinical relevance in liver cancer. **(A)** The mutation rate of *PIGC* is 10%. *PIGC* mutation is significantly correlated with T stage **(B)**, M stage **(C)**, surgical margin resection status **(D)**, and fraction genome alteration **(E)**.

the *PIGC* gene mutation and clinical features. As shown in Figure 5, *PIGC* gene mutation was associated with T stage (Figure 6B), M stage (Figure 6C), surgical margin resection status (Figure 6D), and fraction genome alteration (Figure 6E), while no association was found between the *PIGC* mutation and AFP level, TNM stage, and Child–Pugh classification grade (Table S2). According to the *PIGC* mutation status, we divided the HCC patients into the altered group and unaltered group. Kaplan–Meier curves showed that patients in the unaltered group have a relatively longer OS time compared with patients in the altered group (69.51 vs 30.58 months, Figure S5A), while the difference was insignificant via log rank test ($P=0.0755$). Similarly, HCC patients in the unaltered group exhibited relatively longer DFS time compared with patients in the altered group (23.62 vs 13.14 months, Figure S5B), while the difference was still insignificant via log rank test ($P=0.148$).

Effect of *PIGC* Overexpression and Silencing on Proliferation and Migration

We first determined the *PIGC* protein expression in cancerous liver cell lines (HepG2, Huh7, Hcclm3, and Hep3B) and normal liver cell line (LO2), and the Western blot results revealed that protein levels of *PIGC* were significantly higher in liver cancerous cell lines than in the normal liver cell line (Figure 7A). Among the four liver cancerous cell lines, HepG2 expressed the highest *PIGC* protein, while Hcclm3 expressed the lowest *PIGC* protein. Hence, we knocked out *PIGC* in HepG2 cell line and overexpressed *PIGC* in Hcclm3 cell line. Among the 3 Si-RNAs against *PIGC*, Si-*PIGC*-2 exhibited the highest efficiency as revealed by Western blot (Figure 7B), so we chose Si-*PIGC*-2 for the following experiments. The migration assay (Figure 7C and D) demonstrated that the migrated cells in *PIGC*-silenced HepG2 are significantly decreased compared with that in controlled cancer




Figure 7 Expression of *PIGC* and effects of *PIGC* on proliferation and migration in liver cancer cell lines. (A) Expression of *PIGC* protein is higher in liver cancer cell lines than in normal liver cell line. (B) Si-*PIGC*-2 is the most efficient Si-RNA revealed by Western blot. (C) *PIGC* contributes to the migration of cancerous liver cells. (D) Quantitative analysis of migrated cells in four groups. (E) *PIGC* contributes to the proliferation of cancerous liver cells. *Stands for the P value less than 0.05.

cells (45.0 ± 5.1 vs 72.11 ± 5.11), while the migrated cells are increased in *PIGC*-overexpressed Hcclm3 (91.89 ± 5.16 vs 51.67 ± 5.59). Moreover, to explore the functional role of *PIGC* in regulating the proliferation of liver cancerous cells, we determined the proliferation rate in HepG2 and Hcclm3 cancer cells following silencing or overexpression of *PIGC*. Results of CCK-8 assay revealed that the proliferation rate of *PIGC*-silenced HepG2 cells is significantly lower than that of the corresponding controlled cells ($46.66 \pm 5.05\%$ vs $100 \pm 6.67\%$), whereas the overexpression of *PIGC* in Hcclm3 cells drastically increased cell proliferation ($119.6 \pm 7.47\%$ vs $63.94 \pm 7.17\%$, Figure 7E). Taken together, our results provided solid evidence that *PIGC* takes a crucial role in the proliferation and migration of cancerous liver cells.

Effect of *PIGC* Overexpression and Silencing on the Cell Cycle Pathway

First, we searched the cBioPortal webpage to identify the significant genes which are correlated with the expression of *PIGC* based on the TCGA-LIHC dataset. Then, we selected the genes ($|Pearson\ r| > 0.5$, $P < 0.05$) and entered into the ClueGO app using the Cytoscape software for the analysis of KEGG pathways. Among the significant biological pathways (Figure S6), we found that these co-expressed genes were mostly enriched in the cell cycle checkpoint, regulation of mRNA splicing, RNA export from nucleus, regulation of transcription by RNA polymerase III, ATP-dependent chromatin remodeling, protein K48-linked deubiquitination, etc. As the enrichment analysis suggests that *PIGC* co-expressed genes are mainly enriched in the regulation of the cell cycle checkpoint, we initially applied to validate the bioinformatic conclusion. Flow cytometric analysis showed that G0/G1 ratio was increased in *PIGC*-silenced HepG2 cell line compared to the Si-NC cell line ($58.90 \pm 1.41\%$ vs $52.12 \pm 1.34\%$, Figure 8A and B). Conversely, G0/G1 ratio was dramatically reduced in *PIGC*-overexpressed Hcclm3 cell line compared to the Hcclm3 cell line transfected with the empty vector ($42.94 \pm 0.27\%$ vs $56.60 \pm 0.84\%$, Figure 8C and D). Furthermore, we also investigated the expression of CDKs via Western blot in *PIGC* overexpression and silencing cancerous liver cell lines. When we knocked out the *PIGC* gene in the HepG2 cell line, the expressions of *Cyclin D1*, *CDK2*, *CDK4*, and *CDK6* were all reduced, whereas the expressions of *Cyclin D1*, *CDK2*, *CDK4*, and *CDK6* were significantly upregulated in the *PIGC*-overexpressed Hcclm3 cell line (Figure 8E and F).

Discussion

HCC is one of the most prevalent malignant lesions in China, accounting for substantial mortality.⁵ Therefore, a full understanding of its molecular mechanisms may contribute to discover novel molecular targets for effective treatment. In the current study, we found that expression of *PIGC* is upregulated in HCC, and both overexpression and *PIGC* gene mutations correlate to a list of important features. Moreover, the overexpression of *PIGC* mRNA predicts worse survival (both OS and PFS) among patients with HCC. A series of cellular experiments were conducted to further validate the results generated by comprehensive bioinformatics analysis, and we found that *PIGC* could promote the proliferation and migration of liver cancerous cells and also inhibit the cell cycle. For the first time, our study elaborated on the prognostic value of *PIGC* for HCC and preliminarily explored the underlying molecular mechanisms of *PIGC* in the pathogenesis of HCC.

Whether *PIGC* is an oncogene or a tumor suppressor is still unknown. This study demonstrated that expression of *PIGC* was remarkably upregulated in cancerous liver cell lines, which was in line with the results from the TCGA dataset and Oncomine database. Moreover, based on 362 cases of HCC patients from TCGA-LIHC, we found that high expression of *PIGC* was associated with more malignant features, such as higher tumor grade, lymphatic metastasis, advanced TNM stage, and TP53 mutation. Moreover, we observed that the mutation rate of *PIGC* was 10% among 370 cases of HCC patients, and amplification was the most common mutation type, which was consistent with the overexpression of *PIGC* in cancerous liver tissues. Further statistical analysis revealed that *PIGC* mutation was significantly correlated with T stage and M stage. Hence, we concluded that *PIGC* might be an oncogene in HCC, and overexpression or mutation signifies aggressive features.

Few studies have investigated molecular biomarkers of HCC,²⁴⁻²⁶ and the mechanism of HCC seems to be well understood, but the prognosis of HCC patients is still unsatisfactory. Hence, we urgently need to identify novel markers with great prognostic significance, including the molecular targets for HCC. Our study reveals that HCC patients with high expression of *PIGC* have shorter OS time than those with low expression of *PIGC*. Moreover, overexpression of *PIGC* is a risk factor for worse DFS in patients with HCC. As for the *PIGC* gene mutation, HCC




Figure 8 Effects of *PIGC* on the cell cycle in liver cancer cell line. (A–D) Flow cytometric analysis showed that G0/G1 ratio was increased in *PIGC*-silenced HepG2 cell line (B) compared to the Si-NC cell line (A). G0/G1 ratio was dramatically reduced in *PIGC*-overexpressed Hcclm3 cell line (D) compared to the Hcclm3 cell line transfected with the empty vector (C). Quantitative analysis of G0/G1 ratio in four groups (E). Expression of CDK protein in *PIGC*-silenced and *PIGC*-overexpressed cell lines (F). *Stands for the P value less than 0.05.

patients without *PIGC* mutation exhibited more favorable OS than those with *PIGC* mutation, but the difference between *PIGC* altered and *PIGC* unaltered groups was statistically insignificant due to the limited number of patients with *PIGC* mutation. Similarly, the *PIGC* altered group exhibited shorter DFS time compared with the *PIGC* unaltered group. Therefore, *PIGC* mRNA is a novel biomarker for the prediction of survival among patients with HCC.

Through enrichment analysis, we noticed that *PIGC* co-expressed genes were involved in several important biological pathways in HCC, and cell cycle checkpoint was the most significant pathway. Cell cycle checkpoint plays a vital role in the induction and metastasis of HCC.^{27–29} Further experiments were also conducted to verify this bioinformatic finding. Flow cytometric analysis revealed that the ratio of G0/G1 was significantly decreased when we overexpressed *PIGC* in cancer cells, and the ratio of G0/G1 was obviously increased when we silenced *PIGC* in cancer cells. Moreover, HCC generally occurs with the abnormal activation of CDKs that regulate the cell cycle.³⁰ Abnormal expression of CDKs usually leads to the APC being out of control and the cell cycle progressing into anaphase when chromosomes have not been correctly separated, accordingly leading to the induction of HCC.³¹ We detected these common CDKs via Western blot in *PIGC* silenced and *PIGC* overexpressed cancer cells. Unexpectedly, silence of *PIGC* leads to the downregulation of these CDKs, and overexpression of *PIGC* results in the upregulation of these CDKs. Hence, we infer that *PIGC* contributes to the proliferation and migration, at least partly by upregulating the cell cycle.

Although this is the first study to illuminate the clinical and prognostic relevance and potential biological function of *PIGC* in HCC, several questions were not answered in the present study, and further investigation related to *PIGC* in HCC is still necessary in the future. First, is the expression of *PIGC* protein different between cancerous liver tissues and normal tissues? Second, can *PIGC* serve as a diagnostic biomarker for HCC? Third, does the negative association between *PIGC* expression and DNA methylation still exist in clinical samples? Lastly, will the inhibition of *PIGC* through a small molecular inhibitor in cancerous liver cells be effective?

Conclusion

Our study found that the expression of *PIGC* was upregulated in HCC tissues and correlated with aggressive clinical features. *PIGC* is a novel biomarker for the prediction

of survival in patients with HCC and could contribute to the proliferation and migration of liver cancerous cells through the regulation of cell cycle checkpoints. *PIGC* might serve as a potential oncogene in the pathogenesis and progression of HCC.

Data Sharing Statement

All data generated or analyzed during this study are included in this article and its [Supplementary Information Files](#).

Funding

This study was supported by the Fundamental Research Funds of Wuhan University (NO.2042019kf0059).

Disclosure

The authors declare that they have no competing interests.

References

1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. *CA Cancer J Clin*. 2019;69:7–34. doi:10.3322/caac.21551
2. Villanueva A. Hepatocellular Carcinoma. *N Engl J Med*. 2019;380:1450–1462. doi:10.1056/NEJMr1713263
3. Craig AJ, von Felden J, Garcia-Lezana T, Sarcognato S, Villanueva A. Tumour evolution in hepatocellular carcinoma. *Nat Rev Gastroenterol Hepatol*. 2020;17:139–152. doi:10.1038/s41575-019-0229-4
4. Centers For Disease Control And Prevention, Statistics. NCFH. Trends in liver cancer mortality among adults aged 25 and over in the United States, 2000–2016; 2018.
5. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. *CA Cancer J Clin*. 2015;65:87–108. doi:10.3322/caac.21262
6. Anwanwan D, Singh SK, Singh S, Saikam V, Singh R. Challenges in liver cancer and possible treatment approaches. *Biochim Biophys Acta Rev Cancer*. 2020;1873:188314. doi:10.1016/j.bbcan.2019.188314
7. El-Serag HB, Marrero JA, Rudolph L, Reddy KR. Diagnosis and treatment of hepatocellular carcinoma. *Gastroenterology*. 2008;134:1752–1763. doi:10.1053/j.gastro.2008.02.090
8. Barsoum FS, Awad AS, Hussein NH, Eissa RA, El TH. MALAT-1: lncRNA ruling miR-182/PIG-C/mesothelin triad in triple negative breast cancer. *Pathol Res Pract*. 2020;216:153274. doi:10.1016/j.prp.2020.153274
9. Wang LN, Gao MH, Wang B, Cong BB, Zhang SC. A role for GPI-CD59 in promoting T-cell signal transduction via LAT. *Oncol Lett*. 2018;15:4873–4881. doi:10.3892/ol.2018.7908
10. Loertscher R, Lavery P. The role of glycosyl phosphatidylinositol (GPI)-anchored cell surface proteins in T-cell activation. *Transp Immunol*. 2002;9:93–96. doi:10.1016/s0966-3274(02)00013-8
11. Leidich SD, Kostova Z, Latek RR, et al. Temperature-sensitive yeast GPI anchoring mutants *gpi2* and *gpi3* are defective in the synthesis of N-acetylglucosaminyl phosphatidylinositol. Cloning of the *GPI2* gene. *J Biol Chem*. 1995;270:13029–13035. doi:10.1074/jbc.270.22.13029
12. Edvardson S, Murakami Y, Nguyen TT, et al. Mutations in the phosphatidylinositol glycan C (*PIGC*) gene are associated with epilepsy and intellectual disability. *J Med Genet*. 2017;54:196–201. doi:10.1136/jmedgenet-2016-104202

13. Schleinitz D, Kloting N, Lindgren CM, et al. Fat depot-specific mRNA expression of novel loci associated with waist-hip ratio. *Int J Obes*. 2014;38:120–125. doi:10.1038/ijo.2013.56
14. Wang T, Liu H, Pei L, et al. Screening of tumor-associated antigens based on Oncomine database and evaluation of diagnostic value of autoantibodies in lung cancer. *Clin Immunol*. 2020;210:108262. doi:10.1016/j.clim.2019.108262
15. Tang Z, Kang B, Li C, Chen T, Zhang Z. GEPIA2: an enhanced web server for large-scale expression profiling and interactive analysis. *Nucleic Acids Res*. 2019;47:W556–W560. doi:10.1093/nar/gkz430
16. Chandrashekar DS, Bashel B, Balasubramanya S, et al. UALCAN: a portal for facilitating tumor subgroup gene expression and survival analyses. *Neoplasia*. 2017;19:649–658. doi:10.1016/j.neo.2017.05.002
17. Nasif D, Campoy E, Laurito S, et al. Epigenetic regulation of ID4 in breast cancer: tumor suppressor or oncogene? *Clin Epigenetics*. 2018;10:111. doi:10.1186/s13148-018-0542-8
18. Sun CC, Li SJ, Hu W, et al. Comprehensive analysis of the expression and prognosis for E2Fs in human breast cancer. *Mol Ther*. 2019;27:1153–1165. doi:10.1016/j.ymthe.2019.03.019
19. Yu T, Jia W, An Q, Cao X, Xiao G. Bioinformatic analysis of GLI1 and related signaling pathways in chemosensitivity of gastric cancer. *Med Sci Monit*. 2018;24:1847–1855. doi:10.12659/msm.906176
20. Wilting RH, Dannenberg JH. Epigenetic mechanisms in tumorigenesis, tumor cell heterogeneity and drug resistance. *Drug Resist Updat*. 2012;15:21–38. doi:10.1016/j.drug.2012.01.008
21. Long J, Chen P, Lin J, et al. DNA methylation-driven genes for constructing diagnostic, prognostic, and recurrence models for hepatocellular carcinoma. *Theranostics*. 2019;9:7251–7267. doi:10.7150/thno.31155
22. Liu Z, Jiang Y, Yuan H, et al. The trends in incidence of primary liver cancer caused by specific etiologies: results from the Global Burden of Disease Study 2016 and implications for liver cancer prevention. *J Hepatol*. 2019;70:674–683. doi:10.1016/j.jhep.2018.12.001
23. Islami F, Dikshit R, Mallath MK, Jemal A. Primary liver cancer deaths and related years of life lost attributable to hepatitis B and C viruses in India. *Cancer Epidemiol*. 2016;40:79–86. doi:10.1016/j.canep.2015.11.012
24. Fu Y, Xu X, Huang D, et al. Plasma heat shock protein 90alpha as a biomarker for the diagnosis of liver cancer: an official, large-scale, and multicenter Clinical Trial. *EBioMedicine*. 2017;24:56–63. doi:10.1016/j.ebiom.2017.09.007
25. Zhou F, Shang W, Yu X, Tian J. Glypican-3: a promising biomarker for hepatocellular carcinoma diagnosis and treatment. *Med Res Rev*. 2018;38:741–767. doi:10.1002/med.21455
26. Jiao Y, Li Y, Fu Z, et al. OGDHL expression as a prognostic biomarker for liver cancer patients. *Dis Markers*. 2019;2019:9037131. doi:10.1155/2019/9037131
27. Sosnowska M, Kutwin M, Jaworski S, et al. Mechano-signalling, induced by fullerene C60 nanofilms, arrests the cell cycle in the G2/M phase and decreases proliferation of liver cancer cells. *Int J Nanomed*. 2019;14:6197–6215. doi:10.2147/IJN.S206934
28. Xu SQ, Qin Y, Pan DB, et al. Inhibition of WWP2 suppresses proliferation, and induces G1 cell cycle arrest and apoptosis in liver cancer cells. *Mol Med Rep*. 2016;13:2261–2266. doi:10.3892/mmr.2016.4771
29. Zhu Z, Xiao T, Chang X, Hua Y, Gao J. Morusinol exhibits selective and potent antitumor activity against human liver carcinoma by inducing autophagy, G2/M cell cycle arrest, inhibition of cell invasion and migration, and targeting of Ras/MEK/ERK pathway. *Med Sci Monit*. 2019;25:1864–1870. doi:10.12659/MSM.912992
30. Gao X, Wang Y, Li Y, et al. Hupanpian, a traditional chinese medicine, inhibits liver cancer growth in vitro and in vivo by inducing autophagy and cell cycle arrest. *Biomed Pharmacother*. 2019;120:109469. doi:10.1016/j.biopha.2019.109469
31. Yan H, Li Z, Shen Q, et al. Aberrant expression of cell cycle and material metabolism related genes contributes to hepatocellular carcinoma occurrence. *Pathol Res Pract*. 2017;213:316–321. doi:10.1016/j.prp.2017.01.019

Journal of Hepatocellular Carcinoma

Publish your work in this journal

The Journal of Hepatocellular Carcinoma is an international, peer-reviewed, open access journal that offers a platform for the dissemination and study of clinical, translational and basic research findings in this rapidly developing field. Development in areas including, but not limited to, epidemiology, vaccination, hepatitis therapy, pathology

and molecular tumor classification and prognostication are all considered for publication. The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit <http://www.dovepress.com/testimonials.php> to read real quotes from published authors.

Submit your manuscript here: <https://www.dovepress.com/journal-of-hepatocellular-carcinoma-journal>

Dovepress